Advanced Therapies Integrates 2024

26th November 2024

CORE SECTORS COVERED:

  • TRACK 1: A Digital Revolution & A Person-Centric Approach

SPONSORS INCLUDE:

Cell and Gene Therapy Catapult CPI Mills & Reeve Cytiva Rentschler Biopharma Team Consulting AscellaHealth Stevenage Borough Council

KEY SPEAKERS INCLUDE:

Register Now
Jeanette Evans

Jeanette Evans

Cell and Gene Therapy Catapult
Robert Panting

Robert Panting

Rentschler Biopharma
Debbie Flanagan

Debbie Flanagan

Gilead Sciences
Katy Newton

Katy Newton

Achilles Therapeutics
Miguel Forte

Miguel Forte

Kiji Therapeutics
Mustafa Munye

Mustafa Munye

Complement Therapeutics

AGENDA:

08:30 - 09:30
Registration and Networking
09:30 - 09:40
Welcome & Opening remarks
Matthew Durdy

Matthew Durdy

Cell and Gene Therapy Catapult

09:45 - 10:05
Fireside chat 1
Matthew Durdy

Matthew Durdy

Cell and Gene Therapy Catapult

Nicole Mather

Nicole Mather

Cell and Gene Therapy Catapult

10:10 - 10:30
Fireside chat 2: For the people who need them
A patient group presentation exploring the patient-perspective on the importance of innovations, new gene therapies, and what ATMPs mean for the people, families and communities we’re developing them for.
Nicola Redfern

Nicola Redfern

NJ Redfern Ltd

James Kelly

James Kelly

MEF2C Foundation

10:30 - 11:00
Networking Coffee Break

A Digital Revolution & A Person-Centric Approach

11:00 - 11:45

Make them better

Digital technologies offer new opportunities to overcome key challenges in ATMP manufacturing, such as quality control, efficiency and sustainability. How is the UK embracing these opportunities to make ATMPs faster and more efficiently?

Facilitated by

Stephen Ward

Cell and Gene Therapy Catapult

PANELLISTS

  • Rebecca Street | RoslinCT
  • Katy Newton | Achilles Therapeutics
  • Antoine Espinet | MicrofluidX
  • Edwin Stone | Cellular Origins
  • Kwok Pang | Adthera Bio

Headline Sponsor:

11:50 - 12:35

It’s an upskill battle

Manufacturing ATMPs requires advanced and constantly evolving skills. How can industry and government work together to ensure the UK has the skilled workforce needed for the growth of the ATMP sector?

Facilitated by

Ian Parnham

Cell and Gene Therapy Catapult

PANELLISTS

  • James Kusena | MFX
  • Mustafa Munye | Complement Therapeutics
  • Ketki Vispute | Autolus
  • Saerah Khan | Rentschler Biopharma
  • Dharmesh Vara | Cytiva
  • Anji Miller | LifeArc

12:35 – 13:35

Networking Lunch

Gold and Silver Sponsors:

13:35 - 13:55

Fireside chat 3: From lab to market: The CGT biotech journey

How to succeed in the cell and gene therapy (CGT) space? An insightful session that will delve into the critical factors and strategies for CGT biotech companies to accelerate their journey from lab through clinical development to commercialization.

Facilitated by

Robert Panting

Rentschler Biopharma

14:00 - 14:45

Hub-ble Bubble

The UK is home to world-class innovation hubs and science parks. How do these hubs support the collaboration and sharing of facilities and expertise required for successful ATMP development?

Facilitated by

James Fry

Mills & Reeve

PANELLISTS

  • Sally Ann Forsyth OBE | Stevenage Bioscience Catalyst
  • Michael Baker | FUJIFILM Diosynth Biotechnologies
  • Tom Pike | Stevenage Borough Council
  • Juliana Haggerty | CPI
  • Gillian Molloy | AscellaHealth

14:50 - 15:35

Investing in our health

We need to get advanced therapies to the people who need them rapidly and cost-effectively. How can we improve the bench to bedside journey to cut costs and improve efficiencies? How can we ensure the UK sees ATMPs as an investment in our health and economy?

Facilitated by

Nicola Redfern

NJ Redfern Ltd

PANELLISTS

  • Miguel Forte | Kiji Therapeutics
  • Eric Halioua | PDC*line Pharma
  • Debbie Flanagan | Gilead Sciences
  • James Rutley | Autolomous
  • Moin Saleem | University of Bristol
  • William Scott | Newcastle University Medical School

15:40 – 16:10

Funding battles

In the current economic environment, both public and private funders are tightening their purse strings. How can we demonstrate the health and economic benefits that would come from a return to previous levels of funding for the ATMP sector?

Facilitated by

Jeanette Evans

Cell and Gene Therapy Catapult

PANELLISTS

  • Sam Goldsmith | Cell and Gene Therapy Catapult
  • Karolina Zapadka | Parkwalk Advisors
  • Abigail Martin | ImmuONE

16:10 – 17:10

Networking Drinks Reception

EVENT SPONSORS:

VENUE:

GSK, Stevenage

GSK, Stevenage

GSK, Stevenage

The R&D hub in Stevenage is home to more than 2,500 GSK people focused on discovering and developing new medicines.

The Stevenage Campus base is home to other major organisations including Stevenage Bioscience Catalyst, the Cell and Gene Therapy Manufacturing Catapult, LifeArc and Cytiva alongside a growing cluster of start-up companies.

Options:

By car:
– 20-minute drive to Luton

By train:

-21 minutes from Kings Cross
-35 Minutes from Cambridge

Please click here for directions.

 

Address:

GSK, Gunnels Wood Rd, Stevenage SG1 2NFX

EVENT SPONSORS: